This welcome news from the US signals a step towards a world where Alzheimer’s disease is treatable, but should also serve as a wake-up call.
Today’s ruling involved careful review of data from a rigorous study of 1,800 patients. A similar process is currently underway in the UK, led by the Medicines and Healthcare products Regulatory Agency (MHRA). We’ve written to the MHRA urging them to complete this review as a matter of urgency, without compromising on quality, so people with Alzheimer’s in the UK aren’t left in limbo. We believe that a rapid regulatory decision on lecanemab will further strengthen the UK’s international reputation as a leader in dementia, attract even greater commercial investment in UK clinical trials, and ultimately benefit the one in two of us who will either develop dementia in the future, or care for someone who has it.
With a UK decision on the horizon, today’s news underlines the urgency of getting the NHS ready for new medicines like lecanemab. There are several barriers that need to be tackled, starting with an overhaul of the way dementia is diagnosed. People won’t be able to access these drugs without a confirmed diagnosis of Alzheimer’s, but this is primarily done using a PET scan and the UK has one of the lowest numbers of scanners per capita in the developed world. We’re concerned that, without action, this would significantly restrict access and create inequities in care.
Looking further ahead, new diagnostics are on the horizon – blood tests for Alzheimer’s have been developed, and we’re supporting research to hasten their use in clinical practice. So lecanemab’s potential arrival should act as a warning to accelerate work on this front, and help ensure people who could benefit from these new medicines are identified quickly.
Progress for people with Alzheimer’s disease is long overdue. As a first-generation treatment, lecanemab’s effects are modest – a 27% slowing of progression over 18 months – and it comes with side effects that can be serious. Science can, and must, do better – both in terms of delivering drugs that are even more effective, with fewer side effects, and also treatments for people with later stage Alzheimer’s and those with other forms of dementia. At Alzheimer’s Research UK, we will work tirelessly to help bring about a world free from the heartbreak of dementia, and for a cure for the diseases that cause it.